Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > About the Pancreatic Cancer Action Network (PanCAN)

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 29, 2023 5:26pm

123 Views

Post# 35706517

RE:RE:RE:RE:RE:RE:About the Pancreatic Cancer Action Network (PanCAN)

We’ve established our presence in Basel (Switzerland) in 2016. We’ve grown significantly. We launched Vants and sold Vants. We’re building new Vants in Basel as we speak. We see Basel as a core R&D drug development hub for Roivant and we hope to be an end-to-end pharma company in Basel.

Christian MauriandGlobal Head of Corporate Development at Roivant

<< Previous

Bullboard Posts

Next >>

ArcStone-Kingswood Growth Summit 2024: A premier growth conference